Table S2.
Overall comparison of short-term (30-day) and long-term (180-day) secondary outcomes by attendance status
| Outcome | Attended, mean (95% CI) | Absence, mean (95% CI) | Difference, mean (95% CI) | P-value |
|---|---|---|---|---|
| 30-Day outcomes | ||||
| Serum potassium | 4.73 (4.72, 4.75) | 4.73 (4.69, 4.77) | 0.00 (−0.04, 0.04) | 0.91 |
| Hemoglobin | 10.93 (10.90, 10.96) | 10.75 (10.69, 10.81) | −0.18 (−0.25, −0.12) | <0.001 |
| Ultrafiltration rate | 9.76 (9.59, 9.93) | 9.94 (9.12, 10.75) | 0.18 (−0.65, 1.00) | 0.68 |
| Ultrafiltration volume | 2.67 (2.64, 2.70) | 2.61 (2.52, 2.70) | −0.06 (−0.15, 0.04) | 0.26 |
| Blood pressure | 147.3 (146.8, 147.8) | 147.6 (146.4, 148.8) | 0.3 (−1.0, 1.6) | 0.68 |
| ESA administrations | 7.85 (7.74, 7.96) | 7.68 (7.43, 7.93) | −0.17 (−0.44, 0.10) | 0.22 |
| ESA dosea | 4594 (4494, 4693) | 4775 (4535, 5016) | 181 (−77, 439) | 0.17 |
| ESA utilizationb | 3953 (3859, 4047) | 4060 (3835, 4284) | 107 (−135, 348) | 0.39 |
| 180-Day outcomes | ||||
| Serum potassium | 4.75 (4.74, 4.76) | 4.75 (4.72, 4.77) | 0.00 (−0.04, 0.03) | 0.78 |
| Hemoglobin | 10.93 (10.91, 10.96) | 10.85 (10.8, 10.9) | −0.08 (−0.14, −0.03) | 0.003 |
| Ultrafiltration rate | 9.72 (9.62, 9.83) | 10.03 (9.25, 10.81) | 0.31 (−0.48, 1.09) | 0.44 |
| Ultrafiltration volume | 2.66 (2.63, 2.69) | 2.62 (2.54, 2.7) | −0.04 (−0.12, 0.05) | 0.39 |
| Blood pressure | 147.3 (146.8, 147.8) | 147.8 (146.7, 149.0) | 0.6 (−0.7, 1.8) | 0.37 |
| ESA administrations | 45.25 (44.66, 45.83) | 42.39 (41.12, 43.67) | −2.85 (−4.25, −1.46) | <0.001 |
| ESA dosea | 4583 (4495, 4672) | 4862 (4639, 5085) | 278 (39, 518) | 0.02 |
| ESA utilizationb | 4160 (4074, 4246) | 4429 (4212, 4646) | 269 (37, 502) | 0.02 |
Notes:
a
Among patients receiving ESA.
b
Among all patients (users and nonusers).
Abbreviations: CI, confidence interval; ESA, erythropoiesis-stimulating agent.